Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma
Yıl: 2022 Cilt: 15 Sayı: 3 Sayfa Aralığı: 547 - 554 Metin Dili: İngilizce DOI: 10.31362/patd.1013078 İndeks Tarihi: 19-04-2023
Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma
Öz: Purpose: The multidrug resistance 1 (MDR1) gene expression and its epigenetic status may be an important factor in the chemotherapeutic resistance of glioblastoma (GB). The aim of this study was to analyze the effect of the MDR1 promoter methylation status on GB tumor tissue related with patient survival, chemotherapy resistance, and recurrence of the disease.Materials and methods: Thirty-six patients underwent surgery for GB at the Neurosurgery Department of Ankara University School of Medicine. The patients’ clinical information and the MDR1 methylation status of the tumor tissues was compared to determine the effects on patient survival, chemotherapy resistance, and tumor recurrence.Results: Patients with MDR1 methylated GB had statistically significantly (p<0.001) shorter survival times. Early recurrence was detected in 25% of the patients with unmethylated tumor tissues and in 39.3% with hemimethylated tumor tissues.Conclusion: Instead of using the standard chemotherapeutics in all the patients with GB, tissue-specific medications must be chosen while taking into consideration the epigenomic characteristics and expression status of the tumor because of the genetic heterogeneity of GB. This is the first study to show the association between MDR1 promoter methylation and the clinical data of GB in the literature.
Anahtar Kelime: MDR1 promoter metilasyonu temozolomid direncini etkiler mi? Glioblastomlu hastalarda klinik çalışma
Öz: Amaç: Çoklu ilaç direnci 1 (MDR1) gen ekspresyonu ve epigenetik durumu, glioblastomun (GB) kemoterapötik direncinde önemli bir faktör olabilir. Bu çalışmanın amacı, MDR1 promoter metilasyon durumunun, hastanın sağkalımı, kemoterapi direnci ve hastalığın tekrarlaması ile ilgili olarak GB tümör dokusu üzerindeki etkisini analiz etmektir.Gereç ve yöntem: …. Üniversitesi Tıp Fakültesi Beyin Cerrahisi Anabilim Dalı'nda GB tanısı ile ameliyat edilen 36 hastanın verileri incelendi. Hastaların klinik bilgileri ve tümör dokularının MDR1 metilasyon durumu, hastanın sağkalımı, kemoterapi direnci ve tümör nüksü üzerindeki etkilerine yönelik karşılaştırıldı.Bulgular: MDR1’nin metile olduğu GB'li hastalarda istatistiksel olarak anlamlı (p<0,001) daha kısa sağkalım süreleri saptandı. Metile tümör dokusu olan hastaların %25'inde ve hemi-metile tümör dokusu olan hastaların %39,3'ünde erken rekürrens saptandı.Sonuç: GB'li tüm hastalarda standart kemoterapötikleri kullanmak yerine, GB'nin genetik heterojenliği nedeniyle tümörün epigenomik özellikleri ve ekspresyon durumu dikkate alınarak dokuya özgü ilaçlar seçilmelidir. Bu, literatürdeki MDR1 promoter metilasyonu ile GB'nin klinik verileri arasındaki ilişkiyi gösteren ilk çalışmadır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010;9:135. https:// doi.org/10.1186/1476-4598-9-135
- 2. Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009;18:1061- 1083. https://doi.org/10.1517/13543780903052764
- 3. Rosell R, de Las Peñas R, Balaña C, et al. Translational research in glioblastoma multiforme: molecular criteria for patient selection. Future Oncol 2008;4:219-228. https://doi.org/10.2217/14796694.4.2.219
- 4. Endicott JA, Ling V. The biochemistry of P-glycoprotein- mediated multidrug resistance. Annu Rev Biochem 1989;58:137-171. https://doi.org/10.1146/annurev. bi.58.070189.001033
- 5. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-1288. https://doi.org/10.1126/science.6137059
- 6. Feun LG, Savaraj N, Landy HJ. Drug resistance in brain tumors. J Neurooncol 1994;20:165-176. https:// doi.org/10.1007/BF01052726
- 7. Schaich M, Kestel L, Pfirrmann M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 2009;20:175-181. https://doi. org/10.1093/annonc/mdn548
- 8. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31:4085-4091. https://doi.org/10.1200/ JCO.2013.49.6968
- 9. Keskin E, Elmas Ö, Aydin HA, Şimşek K, Gün E, Kalaycı M. Glioblastome multiforme epidemiyolojisi, tedavi seçenekleri ve sağ kalım süresi: retrospektif tek merkezli çalışma. Batı Karadeniz Tıp Dergisi 2021;5:248-255. https://doi.org/10.29058/mjwbs.875041
- 10. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010;12:26-33. https://doi.org/10.1007/s11912-009-0077-4
- 11. Chien CH, Hsueh WT, Chuang JY, Chang KY. Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. J Biomed Sci 2021;28:18. https://doi.org/10.1186/s12929-021- 00717-7
- 12. Tahara T, Shibata T, Yamashita H, et al. Promoter methylation status of multidrug resistance 1 (MDR1) gene in noncancerous gastric mucosa correlates with Helicobacter Pylori infection and gastric cancer occurrence. Cancer Invest 2010;28:711-716. https:// doi.org/10.3109/07357907.2010.483505
- 13. Ambudkar SV, Kimchi Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-7485. https:// doi.org/10.1038/sj.onc.1206948
- 14. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990;265:506-514.
- 15. Takanishi K, Miyazaki M, Ohtsuka M, Nakajima N. Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma. Oncology 1997;54:231-237. https://doi. org/10.1159/000227694
- 16. Scotlandi K, Manara MC, Serra M, et al. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 1999;18:739-746. https://doi.org/10.1038/ sj.onc.1202330
- 17. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-124. https://doi.org/10.1093/ jnci/81.2.116
- 18. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316:1388-1393. https://doi.org/10.1056/NEJM198705283162207
- 19. Matsumoto T, Tani E, Kaba K, et al. Amplification and expression of a multidrug resistance gene in human glioma cell lines. J Neurosurg 1990;72:96-101. https:// doi.org/10.3171/jns.1990.72.1.0096
- 20. Podolski Renić A, Jadranin M, Stanković T, et al. Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing. Cancer Chemother Pharmacol 2013;72:683-697. https://doi.org/10.1007/s00280-013- 2247-1
- 21. Qiu YY, Mirkin BL, Dwivedi RS. MDR1 hypermethylation contributes to the progression of neuroblastoma. Mol Cell Biochem 2007;301:131-135. https://doi. org/10.1007/s11010-006-9404-3
- 22. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-1986. https://doi.org/10.1158/0008- 5472.can-03-3972
- 23. Bastian PJ, Palapattu GS, Yegnasubramanian S, et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 2008;179:529-534. https://doi.org/10.1016/j.juro.2007.09.038
- 24. Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008;71:161- 167. https://doi.org/10.1016/j.urology.2007.09.056
- 25. von Bossanyi P, Diete S, Dietzmann K, Warich Kirches M, Kirches E. Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol 1997;94:605-611. https://doi.org/10.1007/ s004010050756
- 26. Yokogami K, Kawano H, Moriyama T, et al. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? Eur J Nucl Med 1998;25:401- 409. https://doi.org/10.1007/s002590050238
- 27. Abe T, Mori T, Wakabayashi Y, et al. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 1998;40:11- 18. https://doi.org/10.1023/a:1005954406809
- 28. Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 2021;1876:188616. https://doi.org/10.1016/j. bbcan.2021.188616
| APA | güner y, Al-Beyati E, KURT KIZILDOĞAN A, Gokmen D, SAHİN V, Taspinar F, TETİK B, taspinar m, Ugur H (2022). Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. , 547 - 554. 10.31362/patd.1013078 |
| Chicago | güner yahya efe,Al-Beyati Eyyub S M,KURT KIZILDOĞAN ASLIHAN,Gokmen Derya,SAHİN Vedat,Taspinar Filiz,TETİK Bora,taspinar mehmet,Ugur Hasan Caglar Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. (2022): 547 - 554. 10.31362/patd.1013078 |
| MLA | güner yahya efe,Al-Beyati Eyyub S M,KURT KIZILDOĞAN ASLIHAN,Gokmen Derya,SAHİN Vedat,Taspinar Filiz,TETİK Bora,taspinar mehmet,Ugur Hasan Caglar Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. , 2022, ss.547 - 554. 10.31362/patd.1013078 |
| AMA | güner y,Al-Beyati E,KURT KIZILDOĞAN A,Gokmen D,SAHİN V,Taspinar F,TETİK B,taspinar m,Ugur H Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. . 2022; 547 - 554. 10.31362/patd.1013078 |
| Vancouver | güner y,Al-Beyati E,KURT KIZILDOĞAN A,Gokmen D,SAHİN V,Taspinar F,TETİK B,taspinar m,Ugur H Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. . 2022; 547 - 554. 10.31362/patd.1013078 |
| IEEE | güner y,Al-Beyati E,KURT KIZILDOĞAN A,Gokmen D,SAHİN V,Taspinar F,TETİK B,taspinar m,Ugur H "Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma." , ss.547 - 554, 2022. 10.31362/patd.1013078 |
| ISNAD | güner, yahya efe vd. "Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma". (2022), 547-554. https://doi.org/10.31362/patd.1013078 |
| APA | güner y, Al-Beyati E, KURT KIZILDOĞAN A, Gokmen D, SAHİN V, Taspinar F, TETİK B, taspinar m, Ugur H (2022). Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. Pamukkale Tıp Dergisi, 15(3), 547 - 554. 10.31362/patd.1013078 |
| Chicago | güner yahya efe,Al-Beyati Eyyub S M,KURT KIZILDOĞAN ASLIHAN,Gokmen Derya,SAHİN Vedat,Taspinar Filiz,TETİK Bora,taspinar mehmet,Ugur Hasan Caglar Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. Pamukkale Tıp Dergisi 15, no.3 (2022): 547 - 554. 10.31362/patd.1013078 |
| MLA | güner yahya efe,Al-Beyati Eyyub S M,KURT KIZILDOĞAN ASLIHAN,Gokmen Derya,SAHİN Vedat,Taspinar Filiz,TETİK Bora,taspinar mehmet,Ugur Hasan Caglar Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. Pamukkale Tıp Dergisi, vol.15, no.3, 2022, ss.547 - 554. 10.31362/patd.1013078 |
| AMA | güner y,Al-Beyati E,KURT KIZILDOĞAN A,Gokmen D,SAHİN V,Taspinar F,TETİK B,taspinar m,Ugur H Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. Pamukkale Tıp Dergisi. 2022; 15(3): 547 - 554. 10.31362/patd.1013078 |
| Vancouver | güner y,Al-Beyati E,KURT KIZILDOĞAN A,Gokmen D,SAHİN V,Taspinar F,TETİK B,taspinar m,Ugur H Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma. Pamukkale Tıp Dergisi. 2022; 15(3): 547 - 554. 10.31362/patd.1013078 |
| IEEE | güner y,Al-Beyati E,KURT KIZILDOĞAN A,Gokmen D,SAHİN V,Taspinar F,TETİK B,taspinar m,Ugur H "Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma." Pamukkale Tıp Dergisi, 15, ss.547 - 554, 2022. 10.31362/patd.1013078 |
| ISNAD | güner, yahya efe vd. "Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma". Pamukkale Tıp Dergisi 15/3 (2022), 547-554. https://doi.org/10.31362/patd.1013078 |
